» Articles » PMID: 17719477

(18)Fluorodeoxyglucose Positron Emission Tomography Imaging of Atherosclerotic Plaque Inflammation is Highly Reproducible: Implications for Atherosclerosis Therapy Trials

Overview
Date 2007 Aug 28
PMID 17719477
Citations 191
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: This study tested the near-term reproducibility of (18)fluorodeoxyglucose positron emission tomography (FDG-PET) imaging of atherosclerosis.

Background: It is known that FDG-PET can measure inflammation within the aorta, carotid, and vertebral arteries with histologic validation in humans and animal models of disease. By tracking changes in inflammation over time, PET could be used as a surrogate marker of antiatheroma drug efficacy. However, the short-term variability and reproducibility of the technique are unknown.

Methods: We imaged the carotid arteries and aorta in 11 subjects with FDG-PET/computed tomography twice, 14 days apart. We assessed interobserver and intraobserver agreement and interscan variability.

Results: Interscan plaque FDG variability over 2 weeks was very low; intraclass correlation coefficients (ICC) ranged between 0.79 and 0.92. Interobserver agreement was high across all territories imaged except aortic arch (ICC values from 0.90 to 0.97, arch 0.71). Intraobserver agreement was high, with ICC values between 0.93 and 0.98.

Conclusions: Spontaneous change in plaque FDG uptake is low over 2 weeks, with favorable inter- and intraobserver agreement. Power calculations suggest that drug studies using FDG-PET imaging would require few subjects compared with other imaging modalities. This study strengthens the case for FDG-PET as a noninvasive plaque imaging technique.

Citing Articles

Beyond the Lumen: Molecular Imaging to Unmask Vulnerable Coronary Plaques.

Currie G, Kiat H J Cardiovasc Dev Dis. 2025; 12(2).

PMID: 39997485 PMC: 11856627. DOI: 10.3390/jcdd12020051.


Coronary artery calcifications are not associated with epicardial adipose tissue volume and attenuation on computed tomography in 1,945 individuals with various degrees of glucose disorders.

Molnar D, Bjornson E, Hjelmgren O, Adiels M, Backhed F, Bergstrom G Int J Cardiol Heart Vasc. 2025; 56:101613.

PMID: 39906627 PMC: 11791301. DOI: 10.1016/j.ijcha.2025.101613.


Peptide Receptor Radionuclide Therapy Using Y- and Lu-DOTATATE Modulating Atherosclerotic Plaque Inflammation: Longitudinal Monitoring by Ga-DOTATATE Positron Emissions Tomography/Computer Tomography.

Rubinstein G, Ilhan H, Bartenstein P, Lehner S, Hacker M, Todica A Diagnostics (Basel). 2024; 14(22).

PMID: 39594152 PMC: 11593158. DOI: 10.3390/diagnostics14222486.


Simultaneous 18-FDG PET and MR imaging in lower extremity arterial disease.

Koppara T, Dregely I, Nekolla S, Nahrig J, Langwieser N, Bradaric C Front Cardiovasc Med. 2024; 11:1352696.

PMID: 38404725 PMC: 10884315. DOI: 10.3389/fcvm.2024.1352696.


Increased vascular inflammation on PET/CT in psoriatic arthritis patients in comparison with controls.

Kleinrensink N, Spierings J, Vonkeman H, Seddiqi N, Herman A, Suijkerbuijk K RMD Open. 2024; 10(1).

PMID: 38296307 PMC: 10836343. DOI: 10.1136/rmdopen-2023-003547.